ADVERTISEMENT

From ASCO: Updates in HER2-positive breast cancers

BY DEBU TRIPATHY
PUBLISHED WEDNESDAY, JUNE 5, 2013
Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.



ADVERTISEMENT
ADVERTISEMENT
$auto_registration$